Chow R, Nademanee A, Rosenthal J, Karanes C, Jaing TH, Graham ML, Tsukahara E, Wang B, Gjertson D, Tan P, Forman S, Petz LD. Analysis of hematopoietic cell transplants using plasma-depleted cord blood products that are not red blood cell reduced.  Biology of Blood Marrow Transplant. Nov;13(11):1346-57. 2007.

C Sarkodee-Adoo, J Alvarnas, A Briggs, J Schriber, C Karanes, A Nademanee, R Chiffelle, R Gach, G Sulski, A Rakkar and S Forman.  Emergency double unrelated umbilical cord blood transplant for acute lymphoblastic leukemia after very late deferral of bone marrow donor.  Bone Marrow Transplant. Apr; 41(7): 675-6, 2007.

Ibrahim , Smith MR, Varterasian M, Karanes C, Millenson M, Yeslow G, Pemberton P, Lai P, Abrams J, Al-Katib A.  Phase 2 Study of PEND Chemotherapy in Patients with Refractory/Relapsed Hodgkin Lymphoma. Leukemia Lymphoma. Oct; 45(10): 2079-84, 2004.

Hurley CK, Baxter Lowe LA, Logan B, Karanes C, Anasetti C, Weisdorf, D, Confer DL.  National Marrow Donor Program HLA-matching Guidelines for Unrelated Marrow Transplant.  Biology Blood Marrow Transplant, Oct;9(10):610-5, 2003.

Karanes, C.  Unrelated Donor Stem Cell Transplant: Donor Selection and Search Process.  Pediatric Transplant, 7 Suppl 3:59-64, 2003.

Karanes C, Confer D, Walker T, Askren A, Keller C.  Unrelated Donor Stem Cell Transplantation: the Role of the National Marrow Donor Program.  Oncology, Aug;17(8):1036-8, 1043-4, 1164-7, 2003.

Vaishampayan U, Karanes C, Du W, Varterasian M, Al-Katib A.  Outcome of Relapsed Non-Hodgkin’s Lymphoma Patients After Allogeneic and Autologous Transplantation.  Cancer Invest, 20(3):303-10, 2002.

Larson RA, Boogaerts M, Estey E, Karanes C, Stadmauer EA, Sievers EL, Mineur P, Bennett JM, Berger MS, Eten CB, Munteanu M, Loken MR, Van Dongen JJ, Bernstein ID, Appelbaum FR; Mylotarg Study Group.  Antibody-targeted Chemotherapy of Older Patients With Acute Myeloid Leukemia in First Relapse Using Mylotarg (gentuzumab ozogamicin).  Leukemia, Sep;16(9):1627-36, 2002.

Sievers EL, Larson RA, Stadtmauer A, Estey E, Lowenberg B, Dombret E, Karanes C, Theobald M, Bennett JM, Sherman ML, Berger MS, Eten CB, Loken MR, van Dongen JJM, Bernstein ID, Appelbaum FR for the Mylotarg Study Group.  Efficacy and Safety of Gemtuzumab Ozogamicin in Patients with CD33-Positve Acute Myeloid Leukemia in First Relapse.  Journal of Clinical Oncology, Jul;19(13):3244-54, 2001.

Klein JL, Hamm C, Dansey RD, Karanes C, Abella E, Cassells L, Peters WP, Baynes RD.  High-Dose Chemotherapy and CD34-selected Peripheral Blood Progenitor Cell Transplantation for Patients with Breast Cancer Metastatic to Bone and/or Bone Marrow.  Bone Marrow Transplantation, 28:1023-1029, 2001.

List AF, Kopecky KJ, Willman CL, Head DR, Persons DL, Slovak ML, Dorr R, Karanes C, Hynes HE, Doroshow JH, Shurafa M, Appelbaum FR.  Benefit of Cyclosporine Modulation of Drug Resistance in Patients with Poor-risk Acute Myeloid Leukemia: A Southwest Oncology Group Study.  Blood; 98(12):3212-20, 2001.

Baynes RD, Danesy RD, Klein JL, Karanes C, Cassells L, Hamm C, Abella E, Peters WP.  High-Dose Chemotherapy and Peripheral Blood Progenitor Cell Transplantation for Metastatic and High-Risk Primary Breast Cancer.  Cancer Research Therapy and Control, 11;47-56, 2001.


This is a partial list. Full publications list available upon request. Information on this page may be self-reported and is subject to change at any time. Last updated: 12/08.